The resurgence of Mycoplasma pneumoniae infections and the evolving patterns of antibiotic resistance in the post-pandemic era underscore a pressing challenge for clinicians and public health officials alike. But here’s where it gets controversial—are our current diagnostic and treatment strategies enough to contend with these shifts? And this is the part most people miss: the molecular dynamics of the pathogen itself are changing faster than we can adapt.
In this recent investigation, researchers from McMaster University and affiliated institutions in Hamilton, Ontario, examined the behavior of Mycoplasma pneumoniae, a bacterium responsible for both upper and lower respiratory tract infections, especially in children. It’s a pathogen that can appear in endemic cycles or during epidemics, often causing tracheobronchitis, but most notably, pneumonia, which accounts for approximately 4%–8% of community-acquired bacterial pneumonias during periods of endemicity (1).
Treatment mainly relies on macrolide antibiotics, such as erythromycin or azithromycin. However, the global rise in resistance—where the bacteria no longer respond effectively—is raising serious concerns (2). Since restrictions related to COVID-19 began easing in 2023, surveillance reports note a dramatic increase in M. pneumoniae incidence and outbreaks worldwide (3–5). Specifically, in Ontario, Canada, the detection rate surged up to 30% positivity beginning in May 2024—a stark contrast to the minimal detection rates (around 0.3%) in 2022 and 2023 (6). This study aimed to analyze resistance patterns and genotypes during this outbreak, comparing them to strains collected prior to the pandemic.
Between January 2024 and April 2025, the Hamilton Microbiology Laboratory processed 4,297 nasopharyngeal swab samples from 3,717 patients to detect M. pneumoniae using a specialized PCR test. From the positive samples (a total of 417 after removing duplicates), the team conducted genotyping to detect resistance to macrolides via PCR and analyzed specific gene types, focusing on the P1 cytadhesin gene—a key factor in the bacterium's ability to adhere to respiratory tissues (7). They randomly selected about a quarter of positive samples (110 specimens), spanning different months, for detailed P1 gene sequencing with advanced nanopore technology (Oxford Nanopore). Additionally, they revisited specimens collected from 2013 to 2020 to benchmark resistance trends over time.
The results were striking. By mid-2024, the detection rates had skyrocketed, with about 14.2% of tested patients returning positive for M. pneumoniae. This is a significant jump from less than 1% in previous years. The positivity peaked at an alarming 22.5% in September 2024 before gradually declining below 5% by January 2025, even as testing efforts increased during this period. Resistance to macrolides was present in 11.8% of positive cases overall, with the highest recorded resistance (50%) occurring in July 2024 (Figure 1). Genetic analysis revealed that only one specific mutation—A2063G—was associated with resistance, which is known to produce high-level resistance (erythromycin MIC >64 mg/L). This mutation’s prevalence aligns with earlier findings from Ontario, where over 90% of strains in 2011–2012 carried the same mutation (8).
When examining age groups, children aged 5 to under 18 years exhibited the highest detection rates (~20%), which is expected given their susceptibility. Resistance rates within these children were about 11%, similar to those under 5 and adults aged 18–<65. Interestingly, among older adults over 65, half of the M. pneumoniae strains were resistant—significantly higher than in younger groups (p = 0.02). Although the sample size for this older age group was small (only 6 specimens), this suggests that frequent macrolide use in the elderly might contribute to the increased resistance.
Furthermore, when comparing resistance rates from prior to the pandemic (2013–2020) with the postpandemic period (2024–2025), the figures—17.8% versus 11.8%—did not differ significantly (p = 0.24). This indicates that while overall resistance fluctuates, it has remained relatively stable over nearly a decade. In terms of genotyping, the majority of strains belonged to the P1-1 type (81%), with a smaller fraction being P1-2. Notably, resistance was more common among P1-1 strains (about 30%) than P1-2 strains (about 8%) (p = 0.04). These findings suggest that the molecular epidemiology of M. pneumoniae has shifted quite a bit since 2011–2012, with a dominant P1-1 strain now prevailing in Hamilton, contrasted with earlier data showing a higher prevalence of P1-2.
Genetic analysis of the P1-2 variants uncovered the presence of subtypes like 2g/2j and 2c/2k circulating in Ontario. Although the 2g/2j variants have been present since 2013, their prominence has increased postpandemic, especially the 2c/2k variants. Phylogenetic analysis showed that P1-1 strains from recent years clustered distinctly from older Ontario strains, indicating ongoing evolution in the pathogen’s genetic makeup.
But here’s where it gets thought-provoking: the study highlights some limitations, including the fact that P1 typing was performed only on a subset of samples, focusing solely on the RepMP4 gene region. This means some variant distinctions might not be fully captured. Also, data from the early pandemic years (2013–2016) are sparse, which complicates conclusions about the precise timeline of genotype shifts. Despite these limitations, the study clearly illustrates that M. pneumoniae has undergone significant molecular changes over the past decade, with a notable increase in the dominant P1-1 type and its association with resistance, which previous studies had not observed.
What’s the big takeaway? Although macrolide resistance rates have remained relatively stable, the changing prevalence of P1 genotypes signals an ongoing evolution in the pathogen’s epidemiology. Clinicians should stay vigilant, especially regarding the rising resistance in certain age groups and the new dominant strains circulating in their regions. These shifts could impact treatment effectiveness and require adaptations in diagnostic protocols. The big question remains: Are we prepared to handle these rapid genetic shifts, or are current strategies lagging behind the pathogen’s evolution? Your thoughts in the comments—are we underestimating the speed at which Mycoplasma pneumoniae is changing and resisting antibiotics? Are alternative therapies or new diagnostic methods needed to stay ahead?**
